

[DealPointData.com](https://www.dealpointdata.com)

Sigilon Therapeutics, Inc.

Extract: Charter Amendment (Plain English Desc) from a [8-K](#) on 05/22/2023

[SEC Document](#)

[SEC Filing](#)

On May 22, 2023, the Company filed a Certificate of Amendment (the "Certificate of Amendment") to its Fifth Amended and Restated Certificate of Incorporation (the "Certificate of Incorporation") with the Secretary of State of the State of Delaware to effect a reverse stock split of the Company's issued and outstanding common stock, par value \$0.001 (the "Common Stock"), at a ratio of 1-for-13. As discussed below, on May 19, 2023, the Company's stockholders had approved a proposal to amend the Certificate of Incorporation in accordance with the Certificate of Amendment at the annual meeting of stockholders (the "Annual Meeting"). The Certificate of Amendment is filed as Exhibit 3.1 to this Current Report on Form 8-K. The Company expects that upon the opening of trading on May 23, 2023, the Common Stock will begin trading on a post-split basis under CUSIP number 82657L206.